universal chimeric antigen receptor-modified AT19 cells
/ Wuhan Union Hospital, Chengdu USino Techno
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 15, 2021
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
(clinicaltrials.gov)
- P1; N=27; Recruiting; Sponsor: Wuhan Union Hospital, China
Clinical • New P1 trial • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1